PMLiVE5d
AstraZeneca’s Fasenra receives FDA approval to treat rare inflammatory disease EGPA
Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic ...
Managed Healthcare Executive6d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Medscape6d
FDA Approves Benralizumab for EGPA Vasculitis Indication
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
MedPage Today6d
FDA OKs New Option for Rare Immune-Mediated Vasculitis
EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
EuropaWire6d
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis, Offering New Hope for Patients
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
FiercePharma6d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
EGPA, which was formerly known as Churg-Strauss syndrome, affects roughly 118,000 people worldwide and can often be ...
Joplin Globe6d
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...